A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 July 2016
|
| In: |
BMC cancer
Year: 2016, Jahrgang: 16 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2449-0 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1186/s12885-016-2449-0 Verlag, Volltext: https://doi.org/10.1186/s12885-016-2449-0 
|
| Verfasserangaben: | N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran |
| Zusammenfassung: | Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. |
|---|---|
| Beschreibung: | Gesehen am 15.01.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-016-2449-0 |